EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 03/07/24
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerGlobeNewsWire • 03/04/24
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/29/24
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep goingZacks Investment Research • 02/29/24
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024GlobeNewsWire • 02/29/24
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great ChoiceZacks Investment Research • 02/15/24
Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a BetZacks Investment Research • 02/13/24
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular DegenerationGlobeNewsWire • 02/03/24
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 01/10/24
EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/20/23
EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/11/23
Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to TradeZacks Investment Research • 12/08/23
What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'Zacks Investment Research • 12/08/23
EyePoint announces $175 million stock offering following record surge in share priceMarket Watch • 12/04/23
EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatmentMarket Watch • 12/04/23